John Wells, Adverum (C), Adverum (R), Alimera (R), Bayer (R), Genentech, Inc. (C), Genentech, Inc. (R), Iveric Bio (R), Kodiak Sciences (R), Neurotech (R), Regeneron (R), Roche (C), Roche (R);
Charles Wykoff, Adverum (C), Adverum (R), Allergan (C), Bayer (C), Chengdu Kanghong Biotechnology (C), Chengdu Kanghong Biotechnology (R), Clearside Biomedical (R), EyePoint (C), Genentech, Inc. (C), Genentech, Inc. (R), Graybug Vision (R), Kodiak Sciences (C), Kodiak Sciences (R), Novartis (C), Novartis (R), Opthea (C), Opthea (R), Regeneron (C), Regeneron (R), RegenXBio (C), RegenXBio (R), Roche (C), Roche (R), Samsung Bioepis (R);
Jeffrey Willis, Genentech, Inc. (E);
Zdenka Haskova, Genentech, Inc. (E);
Hugh Lin, Genentech, Inc. (E);
David Silverman, Roche Products Ltd. (E);
Anthony Adamis, Genentech, Inc. (E);
Jane Ives, Roche Products Ltd. (E);
Francis Abreu, Genentech, Inc. (E);
Karen Basu, Roche Products (Ireland) Ltd. (E);
Ramin Tadayoni, AbbVie Allergan (C), AbbVie Allergan (F), AbbVie Allergan (R), Alcon (C), Alcon (F), Apellis (C), Bayer (C), Bayer (F), Bayer (R), Genentech, Inc. (C), Genentech, Inc. (R), Iveric Bio (C), KHB (C), KHB (R), Novartis (C), Novartis (F), Novartis (R), Oculis (C), Oculis (R), Roche (C), Roche (R), Thea (C), Zeiss (F)